---
title: "Cytisinicline in Smoking cessation: Product information and disease description"
description: "Formulary evidence on Cytisinicline in Smoking cessation: Product information and disease description. Covers Product description and Place of product in therapy. 67 evidence topics quoted from 47 sources."
canonical: "https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Cytisinicline in Smoking cessation: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Original NDA submission

> “In June 2025, the company submitted its New Drug Application to the FDA for cytisinicline”

Source: [Achieve Life Sciences public offering pricing announcement (2025)](https://ir.achievelifesciences.com/sec-filings/all-sec-filings/content/0000950170-25-091055/achv-ex99_2.htm)

<a id="topic-2.1.1-2"></a>

##### FDA acceptance and proposed indication

> “the U.S. Food and Drug Administration (FDA) has accepted the cytisinicline New Drug Application (NDA) for a new treatment for smoking cessation in adults.”

Source: [Achieve Life Sciences NDA acceptance announcement (2025)](https://ir.achievelifesciences.com/news-events/press-releases/detail/238/achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation)

<a id="topic-2.1.1-3"></a>

##### Investigational status

> “has not been approved by the Food and Drug Administration for any indication in the United States.”

Source: [Achieve Life Sciences second quarter 2025 results announcement (2025)](https://achievelifesciences.com/achieve-announces-2q25-financial-results/)

<a id="topic-2.1.1-4"></a>

##### FDA complete response letter

> “CRL Cites Deficiencies at Third-Party Manufacturing Facility”
> “No Efficacy or Clinical Safety Deficiencies Identified”

Source: [Achieve Life Sciences complete response letter announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/264/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicline-nda)

<a id="topic-2.1.1-5"></a>

##### Regulatory status: Submission planned; NDA resubmission planned for the fourth quarter of 2026

> “Resubmission of the New Drug Application (NDA) remains on track for the fourth quarter of 2026”

Source: [Achieve Life Sciences third quarter 2026 results announcement (2026)](https://ir.achieverx.com/news-events/press-releases/detail/277/achieverx-reports-third-quarter-2026-financial-results-and-provides-business-updates)

<a id="topic-2.1.1-6"></a>

##### Unfinished product labeling in the complete response letter

> “final product labeling that was not completed by the FDA’s action date.”

Source: [Achieve Life Sciences second quarter 2026 results announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/268/achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-updates)

<a id="topic-2.1.1-7"></a>

##### Launch: Anticipated after potential approval by the end of the second quarter of 2027

> “the Company anticipates potential FDA approval by the end of the second quarter of 2027, with U.S. commercial launch to follow, if approved.”

Source: [Achieve Life Sciences third quarter 2026 results announcement (2026)](https://ir.achieverx.com/news-events/press-releases/detail/277/achieverx-reports-third-quarter-2026-financial-results-and-provides-business-updates)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Name

> “Cytisinicline (known as cytisine)”

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer: Achieve Life Sciences

| Field | Quoted record |
| --- | --- |
| Developer | “Achieve Life Sciences, Inc.” |

Source: [Achieve Life Sciences second quarter 2026 results announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/268/achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-updates)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class

| Receptor activity | Quoted class |
| --- | --- |
| Activity at the α4β2 nicotinic acetylcholine receptor | “partial agonist” |

Source: [Rubinstein and Jacobs (2026b)](https://pubmed.ncbi.nlm.nih.gov/41885134/)

<a id="topic-2.1.2.1-4"></a>

###### U.S. brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### U.S. investigational phase 3 formulation

> “tablets containing 3 mg of cytisinicline”

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="topic-2.1.2.2-2"></a>

###### United Kingdom marketed formulation

| Field | Quoted record |
| --- | --- |
| Dosage form | “Tablet” |
| Strength per tablet | “1.5 mg” |

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="topic-2.1.2.2-3"></a>

###### MedChemExpress research reagent, HY-N0175

> “Product name : Cytisinicline”
> “Catalog No. : HY-N0175”
> “Caution: Product has not been fully validated for medical applications. For research use only.”

Source: [MedChemExpress (2025)](https://file.medchemexpress.com/batch_PDF/HY-N0175/Cytisinicline-SDS-MedChemExpress.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### United States price disclosure

> “the manufacturer has not yet announced a US price for the therapy if approved.”

Source: [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-final-evidence-report-on-medication-for-smoking-cessation/)

<a id="topic-2.1.2.3-2"></a>

###### United Kingdom pricing

> “the company set a price of £115 for a pack of 100 tablets, sufficient for a full treatment course”

Source: [NICE Evidence Review Q (2025)](https://www.ncbi.nlm.nih.gov/books/NBK613971/)

<a id="topic-2.1.2.3-3"></a>

###### United States average sales price and wholesale acquisition cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### United Kingdom ATC classification

| Classification system | Quoted code |
| --- | --- |
| ATC | “N07BA04” |

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed U.S. indication

> “smoking cessation in adults”

Source: [Achieve Life Sciences NDA acceptance announcement (2025)](https://ir.achievelifesciences.com/news-events/press-releases/detail/238/achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action

> “Cytisinicline is a novel smoking cessation medication that acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor, similar to varenicline.”

Source: [Rubinstein and Jacobs (2026b)](https://pubmed.ncbi.nlm.nih.gov/41885134/)

<a id="topic-2.1.2.6.1-2"></a>

###### Nicotine-receptor binding and withdrawal

> “Cytisinicline binds to the same receptors as nicotine to reduce both withdrawal symptoms and satisfaction associated with smoking and vaping.”

Source: [Achieve Life Sciences](https://achievelifesciences.com/products/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### In vitro receptor selectivity

> “Cytisinicline selectively targets the α4β2 nicotinic receptor with minimal interaction with the 5-HT3 receptor.”

Source: [Rubinstein and Jacobs (2026b)](https://pubmed.ncbi.nlm.nih.gov/41885134/)

Additional sources: [Rigotti and Benowitz (2026b)](https://www.tandfonline.com/doi/full/10.1080/14656566.2026.2646283)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics

> “Cytisine was renally excreted and detected as an unchanged drug. No metabolites were detected in plasma or urine collected in the study.”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

Additional sources: [Jeong et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30526213/); [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/); [Tutka et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31240783/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Contraindications: United Kingdom cytisinicline 1.5 mg tablets

> “Unstable angina,”
> “A history of recent myocardial infarction,”
> “Clinically significant arrhythmias,”
> “A history of recent stroke,”
> “Pregnancy and breastfeeding.”

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="topic-2.1.2.7.1-2"></a>

###### Pooled serious adverse-event evidence

> “SAE evidence was limited by imprecision.”

Source: [Livingstone-Banks et al. (2023)](https://www.cochrane.org/evidence/CD006103_can-medications-varenicline-and-cytisine-nicotine-receptor-partial-agonists-help-people-stop-smoking)

<a id="topic-2.1.2.7.1-3"></a>

###### Approved U.S. warnings and precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### United Kingdom 1.5 mg labeling: populations without recommended use

| Population | Quoted recommendation |
| --- | --- |
| Renal or hepatic impairment; adults older than 65 years; persons younger than 18 years | “not recommended” |

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Cytisinicline

<a id="topic-2.1.2.9.1-1"></a>

###### United Kingdom labeling: concomitant antituberculosis drugs

> “Cytisinicline should not be used with anti-tuberculosis drugs.”

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Cytisinicline on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### United Kingdom labeling: systemic hormonal contraceptives

| Question | Quoted evidence status |
| --- | --- |
| Whether cytisinicline reduces the effectiveness of systemic hormonal contraceptives | “currently unknown” |
| Additional contraceptive precaution in the label | “add a second barrier method” |

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dosing studied

> “3mg cytisinicline dosed three times daily for 6 and 12 weeks compared to placebo.”

Source: [Achieve Life Sciences ORCA-2](https://achievelifesciences.com/products/phase-3-orca-2-trial/)

<a id="topic-2.1.2.10.1-2"></a>

###### United Kingdom 1.5 mg regimen: course duration

| Regimen characteristic | Quoted duration |
| --- | --- |
| Labeled treatment course | “25 days” |

Source: [Bonteque Consulting Ltd. Summary of Product Characteristics (2025)](https://www.medicines.org.uk/emc/product/15789/smpc)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### United Kingdom 1.5 mg tablets: oral administration

> “Cytisinicline is for oral use and it should be taken with a suitable amount of water”

Source: [Bonteque Consulting Ltd. patient information leaflet (2025)](https://www.medicines.org.uk/emc/files/pil.15789.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “delivering our investigational therapy to patients through clinical trials”
> “does not have an expanded access program”

Source: [Achieve Life Sciences Expanded Access Policy](https://achievelifesciences.com/products/expanded-access-policy/)

<a id="topic-2.1.2.11-2"></a>

###### United Kingdom 1.5 mg tablets: distributor

| Distribution role | Quoted organization |
| --- | --- |
| Distributor named in the patient leaflet | “Consilient Health Ltd.” |

Source: [Bonteque Consulting Ltd. patient information leaflet (2025)](https://www.medicines.org.uk/emc/files/pil.15789.pdf)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Behavioral support in ORCA-2

> “received standard behavioral support for the duration of the trial.”

Source: [Achieve Life Sciences ORCA-2](https://achievelifesciences.com/products/phase-3-orca-2-trial/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Cytisinicline on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Tobacco use screening and cessation intervention measure

> “Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention”
> “Tobacco Cessation Intervention - Includes brief counseling (3 minutes or less), and/or pharmacotherapy”

Source: [eCQI Resource Center CMS138v14 (2026)](https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS138-v14.0.000-QDM.html)

<a id="topic-2.1.2.13-2"></a>

###### Cytisinicline-specific effect on quality-measure performance

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Cochrane: cytisine versus placebo

> “moderate-certainty evidence (limited by heterogeneity)”
> “RR 1.30, 95% confidence interval (CI) 1.15 to 1.47”
> “4 studies, 4623 participants”

Source: [Livingstone-Banks et al. (2023)](https://www.cochrane.org/evidence/CD006103_can-medications-varenicline-and-cytisine-nicotine-receptor-partial-agonists-help-people-stop-smoking)

<a id="topic-2.1.2.14-2"></a>

###### Systematic review and meta-analyses

| Comparison                                   | Quoted relative effect   | Participants | Certainty  |
| -------------------------------------------- | ------------------------ | -----------: | ---------- |
| Cytisine versus placebo or no medication     | “RR 2.65 (1.50 to 4.67)” |       “5194” | “Moderate” |
| Cytisine versus nicotine-replacement therapy | “RR 1.36 (1.06–1.73)”    |       “1511” | “Moderate” |
| Cytisine versus varenicline                  | “RR 0.96 (0.63–1.45)”    |       “2508” | “Low”      |
| Longer versus shorter treatment duration     | “RR 1.29 (1.02–1.63)”    |       “1009” | “Moderate” |

Source: [Puljević et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/add.16592)

Additional sources: [De Santi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38161271/); [Lindson et al. (2023)](https://doi.org/10.1002/14651858.CD015226.pub2); [Siddiqi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38321591/); [Hajek et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23404838/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Nicotine addiction and tobacco dependence

> “Tobacco dependence is a chronic condition driven by nicotine addiction.”

Source: [VanFrank et al. (2024)](https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Smoking cessation

<a id="topic-2.2.1.2.1-1"></a>

###### Recent successful quitting among U.S. adults in 2022

> “but only 8.8% quit smoking.”

Source: [VanFrank et al. (2024)](https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Smoking cessation

<a id="topic-2.2.1.2.2-1"></a>

###### Current cigarette smoking among U.S. adults in 2022

| Measure | Quoted estimate |
| --- | --- |
| Adult prevalence | “11.6%” |
| Estimated number of adults | “28.8 million” |

Source: [VanFrank et al. (2024)](https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm)

Additional sources: [Agaku (2026)](https://pubmed.ncbi.nlm.nih.gov/41805408/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Mortality from smoking and secondhand smoke in the United States

> “over 480,000 deaths in the U.S. each year.”

Source: [CDC Cigarette Smoking](https://www.cdc.gov/tobacco/about/index.html)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “Nicotine increases dopamine levels, which affect the brain pathways that control reward and pleasure.”

Source: [New York State Department of Health](https://talktoyourpatients.health.ny.gov/nicotine-addiction)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Assessment of tobacco use

> “All patients should be asked about their tobacco use”

Source: [USPSTF (2021)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Nicotine withdrawal: cravings

> “Having urges or cravings to smoke”

Source: [CDC Tips From Former Smokers withdrawal symptoms](https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html)

<a id="topic-2.2.1.6-2"></a>

###### Nicotine withdrawal: irritability and restlessness

> “Feeling irritated, grouchy, or upset”
> “Feeling jumpy and restless”

Source: [CDC Tips From Former Smokers withdrawal symptoms](https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html)

<a id="topic-2.2.1.6-3"></a>

###### Nicotine withdrawal: impaired concentration

> “Having a hard time concentrating”

Source: [CDC Tips From Former Smokers withdrawal symptoms](https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html)

<a id="topic-2.2.1.6-4"></a>

###### Nicotine withdrawal: sleep disturbance

> “Having trouble sleeping”

Source: [CDC Tips From Former Smokers withdrawal symptoms](https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html)

<a id="topic-2.2.1.6-5"></a>

###### Nicotine withdrawal: appetite and weight

> “Feeling hungrier or gaining weight”

Source: [CDC Tips From Former Smokers withdrawal symptoms](https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html)

<a id="topic-2.2.1.6-6"></a>

###### Nicotine withdrawal: anxiety and depressed mood

> “Feeling anxious, sad, or depressed”

Source: [CDC Tips From Former Smokers withdrawal symptoms](https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/7-common-withdrawal-symptoms/index.html)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Smoking-related disease in the United States

> “More than 16 million Americans live with a disease caused by smoking.”

Source: [CDC Cigarette Smoking](https://www.cdc.gov/tobacco/about/index.html)

<a id="topic-2.2.1.7-2"></a>

###### Multiorgan morbidity

> “Smoking harms nearly every organ of the body and causes many diseases.”

Source: [CDC Cigarette Smoking](https://www.cdc.gov/tobacco/about/index.html)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Smoking cessation

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Quality of life after smoking cessation

> “Compared to continuing smokers, quitters showed improved global QOL, HR-QOL, and affect at Years 1 and 3”

Source: [Piper et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3298628/)

Additional sources: [Rubinstein et al. (2026a)](https://achievelifesciences.com/wp-content/uploads/2026/03/ALS28801_26_SRNT_Exit-Interview_Poster_2March2026.pdf)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### United States economic costs of cigarette smoking in 2018

| Cost component | Quoted estimate |
| --- | --- |
| Total cost | “more than an estimated $600 billion” |
| Healthcare spending | “More than $240 billion” |
| Lost productivity from smoking-related illness | “Nearly $185 billion” |
| Lost productivity from smoking-related premature death | “Nearly $180 billion” |
| Lost productivity from premature death caused by secondhand smoke | “About $7 billion” |

Source: [CDC Economic Trends in Tobacco (2024)](https://www.cdc.gov/tobacco/php/data-statistics/economic-trends/index.html)

<a id="topic-2.2.1.8.2-2"></a>

###### Modeled public-health impact

> “both the total number of people who might benefit (71 000) and the potential life-year gains (more than 500 000) are large”

Source: [Reddy et al. (2024)](https://jamanetwork.com/journals/jama-health-forum/fullarticle/2822687)

Additional sources: [Leaviss et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24831822/); [Li et al. (2022)](https://bmjopen.bmj.com/content/12/8/e049644); [Mussio et al. (2026)](https://bmjopen.bmj.com/content/16/2/e113050); [Anraad et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29430762/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Smoking cessation on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Economic costs to smokers and their families

> “Cigarette smoking causes both substantial morbidity and premature mortality, resulting in significant economic costs for smokers and their families”

Source: [U.S. Department of Health and Human Services (2020)](https://www.ncbi.nlm.nih.gov/books/NBK555593/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Nicotine Replacement Therapy

<a id="topic-2.2.2.1.1-1"></a>

###### USPSTF recommendation on tobacco cessation interventions

> “FDA-approved pharmacotherapy for cessation includes nicotine replacement therapy, bupropion sustained-release, and varenicline”

Source: [USPSTF (2021)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Aminoketone Antidepressants

<a id="topic-2.2.2.1.2-1"></a>

###### Recommended non-nicotine antidepressant therapy

| Guideline-listed treatment | Quoted medication |
| --- | --- |
| USPSTF smoking-cessation pharmacotherapy | “bupropion sustained-release” |

Source: [USPSTF (2021)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Nicotinic Acetylcholine Receptor Partial Agonists

<a id="topic-2.2.2.1.3-1"></a>

###### WHO tobacco cessation treatment guideline

> “WHO recommends varenicline, Nicotine Replacement Therapy (NRT), bupropion, and cytisine as effective treatments for tobacco cessation.”

Source: [WHO (2024)](https://www.who.int/news/item/02-07-2024-who-releases-first-ever-clinical-treatment-guideline-for-tobacco-cessation-in-adults)

<a id="topic-2.2.2.1.3-2"></a>

###### WHO Essential Medicines List

> “the Expert Committee recommended the addition of cytisine to the core list of the EML as a treatment option for tobacco and smoking cessation.”

Source: [WHO Expert Committee (2025)](https://list.essentialmeds.org/recommendations/1472)

Additional sources: [Rábade-Castedo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37567792/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Behavioral Counseling

<a id="topic-2.2.2.1.4-1"></a>

###### Behavioral interventions combined with pharmacotherapy

> “Combining pharmacotherapy with behavioural interventions significantly increases quitting success rates.”

Source: [WHO (2024)](https://www.who.int/news/item/02-07-2024-who-releases-first-ever-clinical-treatment-guideline-for-tobacco-cessation-in-adults)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Digital Interventions

<a id="topic-2.2.2.1.5-1"></a>

###### Digital adjuncts and self-management tools

> “text messaging, smartphone apps, and internet programmes”

Source: [WHO (2024)](https://www.who.int/news/item/02-07-2024-who-releases-first-ever-clinical-treatment-guideline-for-tobacco-cessation-in-adults)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Electronic Cigarettes

<a id="topic-2.2.2.1.6-1"></a>

###### USPSTF assessment of electronic cigarettes for tobacco cessation

| Assessment | Quoted evidence status |
| --- | --- |
| Evidence to assess the balance of benefits and harms in adults, including pregnant persons | “insufficient” |

Source: [USPSTF (2021)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

In the 2022 U.S. survey, 38.3% of adults who tried to quit used counseling or medication, and recent successful cessation was reported by 8.8%. The cytisine-versus-varenicline evidence in the 2024 meta-analysis was rated low certainty. The Cochrane review identified imprecision in the evidence concerning serious adverse events.

Source: [VanFrank et al. (2024)](https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm); [Puljević et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/add.16592); [Livingstone-Banks et al. (2023)](https://www.cochrane.org/evidence/CD006103_can-medications-varenicline-and-cytisine-nicotine-receptor-partial-agonists-help-people-stop-smoking)

<a id="topic-2.2.2.1.7-2"></a>

###### Smoking cessation and treatment utilization

> “Among those who tried to quit, 38.3% used treatment (i.e., counseling or medication).”

Source: [VanFrank et al. (2024)](https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The proposed U.S. indication is smoking cessation in adults. Development studied oral cytisinicline with behavioral support. WHO includes cytisine among recommended tobacco-cessation pharmacotherapies and recommends combining medication with behavioral interventions. U.S. commercial use remains contingent on FDA approval; the sponsor anticipated potential approval in the first half of 2027.

Source: [Achieve Life Sciences NDA acceptance announcement (2025)](https://ir.achievelifesciences.com/news-events/press-releases/detail/238/achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation); [Achieve Life Sciences ORCA-2](https://achievelifesciences.com/products/phase-3-orca-2-trial/); [WHO (2024)](https://www.who.int/news/item/02-07-2024-who-releases-first-ever-clinical-treatment-guideline-for-tobacco-cessation-in-adults); [Achieve Life Sciences second quarter 2026 results announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/268/achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-updates)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### History of cancer: sponsor-reported pooled ORCA-2 and ORCA-3 analysis

| Treatment | Quoted abstinence rate |
| --- | --- |
| Cytisinicline for 12 weeks | “24.4%” |
| Placebo | “15.8%” |

Source: [Achieve Life Sciences second quarter 2026 results announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/268/achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-updates)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### The five As

> “Ask, Advise, Assess, Assist, Arrange follow-up”

Source: [USPSTF (2021)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### United Kingdom 1.5 mg tablets: suspected adverse-reaction reporting

| Reporting route | Quoted scheme |
| --- | --- |
| National adverse-reaction reporting system | “Yellow Card Scheme” |

Source: [Bonteque Consulting Ltd. patient information leaflet (2025)](https://www.medicines.org.uk/emc/files/pil.15789.pdf)

<a id="topic-2.2.2.6-2"></a>

###### U.S. post-approval monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Health benefits of smoking cessation

> “Quitting smoking improves health and reduces the risk of premature death.”

Source: [CDC Cigarette Smoking](https://www.cdc.gov/tobacco/about/index.html)

## Related pages
- [Cytisinicline: Smoking cessation](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation.md)
- [Cytisinicline in Smoking cessation: Terms and abbreviations](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations.md)
- [Cytisinicline: Smoking cessation](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/executive-summary.md)
- [Cytisinicline in Smoking cessation: Clinical evidence](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/clinical-evidence.md)
- [Cytisinicline in Smoking cessation: Economic information and modeling report](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economics) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economics.md)
- [Cytisinicline in Smoking cessation: References](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references.md)
- [Cytisinicline in Smoking cessation: prevalence by geography](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/prevalence) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/prevalence.md)
- [Cytisinicline in Smoking cessation: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/cost-effectiveness-analyses.md)
